<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00828776</url>
  </required_header>
  <id_info>
    <org_study_id>HEPCRI0907</org_study_id>
    <nct_id>NCT00828776</nct_id>
  </id_info>
  <brief_title>Pharmacodynamics and Non-Clinical Inferiority of Heparin Sodium (Cristália) Compared With the Product Liquemine (Roche) in Chronic Renal Failure</brief_title>
  <acronym>heparin</acronym>
  <official_title>Clinical Trial of Pharmacodynamic Effects and Non-Clinical Inferiority of the Drug Heparin Sodium Produced by the Laboratory Cristália When Compared With the Product Liquemine of Roche Laboratory in Patients With Chronic Renal Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azidus Brasil</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azidus Brasil</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study was to assess the safety in use of the drug Heparin&#xD;
      Sodium, produced by Cristália Laboratory, compared drug Liquemine ®, manufactured by Roche&#xD;
      Laboratory, and secondary purpose was to evaluate the non-inferiority clinical testing of the&#xD;
      product on the product comparator and pharmacodynamic effect, as evidenced by analyzing the&#xD;
      parameters and TTPA Anti-Xa in patients with chronic renal failure in treatment of&#xD;
      hemodialysis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>TTPA Anti-Xa Adverse Reactions</measure>
    <time_frame>12 consecutive sessions of hemodialysis</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Chronic Renal Failure</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Heparin Cristália</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Heparin - Roche</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Heparin sodic - Cristália</intervention_name>
    <description>5000UI/mL</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>heparin - Liquemine (Roche)</intervention_name>
    <description>5000UI/mL</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults of both sexes, regardless of color or social class&#xD;
&#xD;
          -  Age over 18 years with a good clinical medical criteria&#xD;
&#xD;
          -  Patients who agreed to participate and signed the Informed Consent&#xD;
&#xD;
          -  Insufficient patients in chronic renal dialysis schedule (3 times per week)&#xD;
&#xD;
          -  Patients with creatinine clearance &lt;30ml/min&#xD;
&#xD;
          -  Patients with indication for anticoagulation during hemodialysis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with sensitivity to heparin sodium;&#xD;
&#xD;
          -  Patients with hypersensitivity to benzyl alcohol&#xD;
&#xD;
          -  Patients with a history of bleeding or illness that can change the blood coagulation&#xD;
             aggravate or terminate the clinical picture, such as tables of gastric ulcer&#xD;
&#xD;
          -  Patients with a history of peptic ulcer&#xD;
&#xD;
          -  Patients with body mass index greater than 30&#xD;
&#xD;
          -  Cancer patients because of the possibility of compromising the function of the&#xD;
             variable coagulation&#xD;
&#xD;
          -  Patients in period of pregnancy or after delivery&#xD;
&#xD;
          -  Patients with genetic abnormality of the clotting system&#xD;
&#xD;
          -  Polytraumatized patients&#xD;
&#xD;
          -  Patients using glucocorticoids for at least 1 month&#xD;
&#xD;
          -  Patients using other anticoagulants&#xD;
&#xD;
          -  Patients with high rate of bleeding&#xD;
&#xD;
          -  Patients undergoing any surgery performed less than 15 days due to the risk of&#xD;
             training of hematoma at the site of surgery&#xD;
&#xD;
          -  Hypertension above 140/90 mmHg&#xD;
&#xD;
          -  Patients using medications that could affect hemostasis&#xD;
&#xD;
          -  Patients using the following medicines: hormonal anti not including Ketorolac; Dextran&#xD;
             40, ticlopidine and clopidogrel, systemic glucocorticoids, thrombolytic agents and&#xD;
             anticoagulants and other antiplatelet agents, including antagonists of glycoprotein&#xD;
             IIb / IIIa.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Lal Clinica Pesquisa E Desenvolvimento Ltda</name>
      <address>
        <city>Valinhos</city>
        <state>Sao Paulo</state>
        <zip>13270000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>January 2009</verification_date>
  <study_first_submitted>January 23, 2009</study_first_submitted>
  <study_first_submitted_qc>January 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2009</study_first_posted>
  <last_update_submitted>January 23, 2009</last_update_submitted>
  <last_update_submitted_qc>January 23, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2009</last_update_posted>
  <responsible_party>
    <name_title>Alexandre Frederico</name_title>
    <organization>LAL Clinica</organization>
  </responsible_party>
  <keyword>TTPa</keyword>
  <keyword>Anti-Xa</keyword>
  <keyword>Adverse Reactions</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Calcium heparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

